Stabilisation of Laryngeal AL Amyloidosis with Long Term Curcumin Therapy
Table 1
Haematological and biochemical data performed at first visit (February 2006) and at 3 months (2009) after commencing curcumin therapy and thereafter annually (2010–2014).
Variable
2006
2009
2010
March 2013
March 2014
Bone marrow biopsy (% plasma cells)
18
2
5
<2
<2
Paraprotein (g/L)
14
6
1
Trace
Trace
Free light chain ratio (0.3–1.7)
1.7
1.3
0.81
0.68
Lambda FLC (<26.3 mg/L)
9
4
37
40
Kappa FLC (<19.4 mg/L)
15
5
30
27
Globulin (22–38 g/L)
29
23
30
30
Calcium (mmol/L)
2.32
2.34
2.46
Ig G (6.2–14.4 g/L)
20
10.01
9.5
9.5
9.4
Ig M (0.48–3.04 g/L)
0.71
0.85
0.87
0.95
Ig A (0.6–3.96 g/L)
1.63
1.68
1.42
1.35
Haemoglobin (128–175 g/L)
157
120
139
135
136
WCC (4.0–11.0 × 109/L)
6
3.2
4.3
6.8
6.1
Platelets (150–450 × 109/L)
236
114
164
171
174
LDH (u/L)
167
163
133
142
140
B2 microglobulin (g/L)
2.2
2.5
3.1
3.4
3.7
Serum creatinine (60–120 μmol/L)
109
135
127
117
eGFR (>89 mL/min)
57
45
46
51
u-creat (8.8–17.6 mmol/L)
10.3
8.1
6.6
u-prot (0.01–0.20 mg/day)
0.15
0.06
0.05
0.07
After 3 months of curcumin therapy. “u-creat” refers to urinary creatinine and “u-prot” refers to urinary-protein.
